All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2005-003841-14 | A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options | 2006-11-28 | due-trials |
Reported results | 2005-004430-41 | Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. | 2006-03-13 | due-trials |
Reported results | 2006-005609-76 | EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID. | 2007-03-02 | due-trials |
Not reported | 2006-006174-19 | A randomised, open label, phase IV comparative study to determine the effects on renal function of continuing treatment with tenofovir versus replacement with abacavir in HIV positive persons | 2008-04-02 | due-trials |
Not reported | 2007-000932-19 | A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression... | 2008-11-10 | due-trials |
Not reported Terminated | 2008-000604-88 | A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-booste... | 2010-07-12 | due-trials |
Not reported | 2008-000674-20 | A phase III, double blind, multi centre, randomised placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing Central Nervous System (CNS) ... | 2009-07-15 | due-trials |
Not reported Terminated | 2008-006769-95 | A Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study into the Impact of Maraviroc, an Orally Administered CCR5 Inhibitor, on the Intensification of Immune Function i... | 2011-06-02 | due-trials |
Not reported | 2010-018878-21 | A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to ralteg... | 2013-05-13 | due-trials |
Reported results | 2011-001913-14 | A randomized crossover study of the effects of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia | 2012-03-14 | due-trials |
Reported results | 2012-000649-11 | A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study SS... | 2015-11-19 | due-trials |
Reported results | 2012-002205-22 | A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicity, ... | 2013-11-11 | due-trials |
Reported results | 2012-002663-10 | A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV-1 ... | 2015-03-16 | due-trials |
Reported results | 2012-005525-75 | An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype ... | 2016-02-18 | due-trials |
Listed as ongoing, but also has a completion date | 2013-003704-39 | An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppres... | 2017-12-04 | bad-data |
Reported results | 2014-002284-15 | SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from tenof... | 2017-02-10 | due-trials |
Reported results | 2014-004578-40 | A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal tub... | 2017-04-06 | due-trials |